October 1, 2024
View Full PaperFigure 1 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Key Points
Key points are not available for this paper at this time.
Abstract
PFS in patients who received prior ET+CDK4/6i ≥12 months in the metastatic setting. Kaplan–Meier estimates of PFS in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months in the metastatic setting (n = 159).